Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to $145.2 million.

  • Denali Therapeutics' Shares Outstanding (Weighted Average) rose 2.13% to $146.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.2 million, marking a year-over-year increase of 2.13%. This contributed to the annual value of $145.2 million for FY2024, which is 5.08% up from last year.
  • As of FY2024, Denali Therapeutics' Shares Outstanding (Weighted Average) stood at $145.2 million, which was up 5.08% from $138.2 million recorded in FY2023.
  • Over the past 5 years, Denali Therapeutics' Shares Outstanding (Weighted Average) peaked at $145.2 million during FY2024, and registered a low of $121.0 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $138.2 million (2023), whereas its average is $140.0 million.
  • Data for Denali Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 25.98% (in 2020) over the last 5 years.
  • Denali Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $121.0 million in 2020, then grew by 0.94% to $122.1 million in 2021, then climbed by 11.92% to $136.7 million in 2022, then climbed by 1.11% to $138.2 million in 2023, then rose by 5.08% to $145.2 million in 2024.